Journal of Investigative Dermatology, ISSN 0022-202X, 12/2018, Volume 138, Issue 12, pp. e93 - e95
Journal Article
DERMATOLOGIC CLINICS, ISSN 0733-8635, 07/2017, Volume 35, Issue 3, pp. 299 - 299
Atopic dermatitis therapy can be a challenge in many cases. Persistence into adulthood often reflects the more severe cases and such patients have the added...
Systemic therapy | Topical therapy | Atopic dermatitis | Eczema | PREVALENCE | HAND ECZEMA | DERMATOLOGY | Dermatitis, Atopic - diagnosis | Diagnosis, Differential | Dermatitis, Atopic - drug therapy | Humans | Age of Onset | Adult | Secondary Prevention | Administration, Cutaneous | Adrenal Cortex Hormones - therapeutic use
Systemic therapy | Topical therapy | Atopic dermatitis | Eczema | PREVALENCE | HAND ECZEMA | DERMATOLOGY | Dermatitis, Atopic - diagnosis | Diagnosis, Differential | Dermatitis, Atopic - drug therapy | Humans | Age of Onset | Adult | Secondary Prevention | Administration, Cutaneous | Adrenal Cortex Hormones - therapeutic use
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2016
Journal Article
Journal of Allergy and Clinical Immunology, The, ISSN 0091-6749, 2013, Volume 132, Issue 5, pp. 1132 - 1138
Background Little is known about the epidemiology of eczema in adults. The goal of this study was to determine the prevalence of and associations with adult...
Allergy and Immunology | race | ethnicity | atopic dermatitis | asthma | rhinoconjunctivitis | dermatitis | atopic disease | birthplace | Eczema | Hispanic | socioeconomic status | hay fever | age | UNITED-STATES | RISK-FACTORS | CHILDHOOD ECZEMA | IMMUNOLOGY | ATOPIC-DERMATITIS | ALLERGY | JAPANESE ADULTS | DISEASE | COHORT | BIRTH | YOUNG-CHILDREN | United States - epidemiology | Eczema - complications | Prevalence | Humans | Middle Aged | Risk Factors | Hypersensitivity, Immediate - complications | Young Adult | Eczema - epidemiology | Asthma - complications | Adolescent | Aged, 80 and over | Hypersensitivity, Immediate - epidemiology | Adult | Aged | Population Surveillance | Asthma - epidemiology | Adults | Prevalence studies (Epidemiology) | Asthma | Health insurance | Family income | Households | Health care policy | Data processing | Statistical methods | Secondary schools | Hay fever | Educational attainment | Ethnicity | Education | Population | Age
Allergy and Immunology | race | ethnicity | atopic dermatitis | asthma | rhinoconjunctivitis | dermatitis | atopic disease | birthplace | Eczema | Hispanic | socioeconomic status | hay fever | age | UNITED-STATES | RISK-FACTORS | CHILDHOOD ECZEMA | IMMUNOLOGY | ATOPIC-DERMATITIS | ALLERGY | JAPANESE ADULTS | DISEASE | COHORT | BIRTH | YOUNG-CHILDREN | United States - epidemiology | Eczema - complications | Prevalence | Humans | Middle Aged | Risk Factors | Hypersensitivity, Immediate - complications | Young Adult | Eczema - epidemiology | Asthma - complications | Adolescent | Aged, 80 and over | Hypersensitivity, Immediate - epidemiology | Adult | Aged | Population Surveillance | Asthma - epidemiology | Adults | Prevalence studies (Epidemiology) | Asthma | Health insurance | Family income | Households | Health care policy | Data processing | Statistical methods | Secondary schools | Hay fever | Educational attainment | Ethnicity | Education | Population | Age
Journal Article
Pediatrics, ISSN 0031-4005, 12/2015, Volume 136, Issue 6, pp. e1530 - e1530
Children with atopic dermatitis (AD) have a higher risk for development of food allergies. The objective of this study was to examine incidence of food allergy...
Journal Article
Journal of Allergy and Clinical Immunology, The, ISSN 0091-6749, 2014, Volume 134, Issue 4, pp. 818 - 823
Background Atopic dermatitis (atopic eczema) is a chronic inflammatory skin disease that has reached epidemic proportions in children worldwide and is...
Allergy and Immunology | eczema | emollients | skin barrier | Atopic dermatitis | prevention | SUNFLOWER SEED OIL | FILAGGRIN | IMMUNOLOGY | CARE | CHILDREN | CREAM | ALLERGY | INFANTS | PETROLATUM | HEALTH | EXPOSURE | Emollients - administration & dosage | Emollients - immunology | Follow-Up Studies | United States | Humans | Infant | Risk | Treatment Outcome | United Kingdom | Dermatitis, Atopic - prevention & control | Feasibility Studies | Incidence | Dermatitis, Atopic - immunology | Emollients - adverse effects | Infant, Newborn | Skin - drug effects | Skin - pathology | Skin - immunology | Prevention | Dermatology | Formulae, receipts, prescriptions | Dermatologic agents | Skin | Medicine, Preventive | Public health | Preventive health services | Food allergies | Laboratories | Eczema | Mutation | Dermatitis | Allergies | Children & youth | Atopic Dermatitis and Skin Disease
Allergy and Immunology | eczema | emollients | skin barrier | Atopic dermatitis | prevention | SUNFLOWER SEED OIL | FILAGGRIN | IMMUNOLOGY | CARE | CHILDREN | CREAM | ALLERGY | INFANTS | PETROLATUM | HEALTH | EXPOSURE | Emollients - administration & dosage | Emollients - immunology | Follow-Up Studies | United States | Humans | Infant | Risk | Treatment Outcome | United Kingdom | Dermatitis, Atopic - prevention & control | Feasibility Studies | Incidence | Dermatitis, Atopic - immunology | Emollients - adverse effects | Infant, Newborn | Skin - drug effects | Skin - pathology | Skin - immunology | Prevention | Dermatology | Formulae, receipts, prescriptions | Dermatologic agents | Skin | Medicine, Preventive | Public health | Preventive health services | Food allergies | Laboratories | Eczema | Mutation | Dermatitis | Allergies | Children & youth | Atopic Dermatitis and Skin Disease
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2013, Volume 69, Issue 5, pp. e279 - e279
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 09/2016, Volume 75, Issue 3, pp. 504 - 505
pruritus | atopic dermatitis | phosphodiesterase | inflammation | immune responses | VITRO | INHIBITION | DISEASE | HISTAMINE-RELEASE | CYCLIC-AMP-PHOSPHODIESTERASE | DERMATOLOGY | Phosphodiesterase Inhibitors - therapeutic use | Drug Administration Schedule | Phosphodiesterase Inhibitors - adverse effects | Humans | Male | Treatment Outcome | Clinical Trials as Topic | Dermatitis, Atopic - physiopathology | Forecasting | Dose-Response Relationship, Drug | Pruritus - physiopathology | Dermatitis, Atopic - drug therapy | Inflammation - drug therapy | Pruritus - drug therapy | Dermatitis, Atopic - immunology | Female | Inflammation - physiopathology | Drug therapy | Atopic dermatitis
Journal Article
Journal of Allergy and Clinical Immunology, The, ISSN 0091-6749, 2010, Volume 126, Issue 6, pp. 1105 - 1118
 First-line and adjuvant treatment for food-induced anaphylaxis1114 6.3.2. Despite the risk of severe allergic reactions and even death, there is no current...
Allergy and Immunology | ALLERGY | IMMUNOLOGY | Food Hypersensitivity - therapy | United States | Humans | National Institute of Allergy and Infectious Diseases (U.S.) | Expert Testimony | Food Hypersensitivity - diagnosis | Food Hypersensitivity - physiopathology | Allergens | Food allergy | Medical colleges | Care and treatment | Safety and security measures | Emergency medicine | Practice guidelines (Medicine) | Respiratory agents | Asthma | Government finance | Diagnosis | Children | Arctic peoples | Health aspects | Monoglycerides | Food | Food allergies | Disease | Oxygen therapy | Comorbidity | Family medical history | Epidemiology | Patients | Allergies | Tropical diseases | Proteins | Medicine | Disease prevention | Celiac disease | Drug therapy | Drug dosages
Allergy and Immunology | ALLERGY | IMMUNOLOGY | Food Hypersensitivity - therapy | United States | Humans | National Institute of Allergy and Infectious Diseases (U.S.) | Expert Testimony | Food Hypersensitivity - diagnosis | Food Hypersensitivity - physiopathology | Allergens | Food allergy | Medical colleges | Care and treatment | Safety and security measures | Emergency medicine | Practice guidelines (Medicine) | Respiratory agents | Asthma | Government finance | Diagnosis | Children | Arctic peoples | Health aspects | Monoglycerides | Food | Food allergies | Disease | Oxygen therapy | Comorbidity | Family medical history | Epidemiology | Patients | Allergies | Tropical diseases | Proteins | Medicine | Disease prevention | Celiac disease | Drug therapy | Drug dosages
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2017, Volume 376, Issue 9, pp. 826 - 835
In a phase 2, placebo-controlled trial, nemolizumab, an antibody against interleukin-31 receptor A, reduced pruritus in patients with moderate-to-severe atopic...
VISUAL ANALOG SCALE | ACTIGRAPHY | MEDICINE, GENERAL & INTERNAL | ITCH | ECZEMA | SUICIDAL IDEATION | PRURITUS | INTERLEUKIN-31 RECEPTOR | SKIN | T-CELLS | IL-31 | Antibodies, Monoclonal, Humanized - adverse effects | Receptors, Interleukin - immunology | Humans | Middle Aged | Male | Receptors, Interleukin - antagonists & inhibitors | Antibodies, Monoclonal, Humanized - administration & dosage | Dermatitis, Atopic - drug therapy | Pruritus - drug therapy | Intention to Treat Analysis | Adult | Female | Edema - chemically induced | Usage | Care and treatment | Interleukins | Atopic dermatitis | Diagnosis | Pruritus | Patients | Health aspects | Immunoglobulins | Cytokines | Body weight | Eczema | Clinical trials | Surface area | Drug therapy | Dermatitis
VISUAL ANALOG SCALE | ACTIGRAPHY | MEDICINE, GENERAL & INTERNAL | ITCH | ECZEMA | SUICIDAL IDEATION | PRURITUS | INTERLEUKIN-31 RECEPTOR | SKIN | T-CELLS | IL-31 | Antibodies, Monoclonal, Humanized - adverse effects | Receptors, Interleukin - immunology | Humans | Middle Aged | Male | Receptors, Interleukin - antagonists & inhibitors | Antibodies, Monoclonal, Humanized - administration & dosage | Dermatitis, Atopic - drug therapy | Pruritus - drug therapy | Intention to Treat Analysis | Adult | Female | Edema - chemically induced | Usage | Care and treatment | Interleukins | Atopic dermatitis | Diagnosis | Pruritus | Patients | Health aspects | Immunoglobulins | Cytokines | Body weight | Eczema | Clinical trials | Surface area | Drug therapy | Dermatitis
Journal Article
Journal of Allergy and Clinical Immunology, The, ISSN 0091-6749, 2010, Volume 127, Issue 3, pp. 773 - 786.e7
Background Atopic dermatitis (AD) is characterized by dry skin and a hyperactive immune response to allergens, 2Â cardinal features that are caused in part by...
Allergy and Immunology | Atopic dermatitis | claudin-1 | tight junctions | EPIDERMAL BARRIER FUNCTION | WATER-LOSS | IMMUNOLOGY | CLAUDIN EXPRESSION | LANGERHANS CELLS | ALLERGY | GENE-EXPRESSION | INTESTINAL BARRIER | SKIN | PERMEABILITY BARRIER | PROTEINS | SINGLE-NUCLEOTIDE POLYMORPHISMS | Immunohistochemistry | Dermatitis, Atopic - genetics | Dermatitis, Atopic - epidemiology | Membrane Proteins - genetics | Humans | Cells, Cultured | Gene Expression Regulation | Male | Dermatitis, Atopic - pathology | Gene Expression Profiling | Claudin-1 | Tight Junctions - immunology | Age of Onset | Dermatitis, Atopic - immunology | Polymerase Chain Reaction | Adult | Female | Membrane Proteins - metabolism | Polymorphism, Single Nucleotide | Phosphates | Allergens | Medical colleges | Care and treatment | RNA | Radiation | Fluorescein | Permeability | Sugars | Monosaccharides | Proteins | Studies | Antigens | Psoriasis | Disease | Skin diseases | Dermatitis | Defects
Allergy and Immunology | Atopic dermatitis | claudin-1 | tight junctions | EPIDERMAL BARRIER FUNCTION | WATER-LOSS | IMMUNOLOGY | CLAUDIN EXPRESSION | LANGERHANS CELLS | ALLERGY | GENE-EXPRESSION | INTESTINAL BARRIER | SKIN | PERMEABILITY BARRIER | PROTEINS | SINGLE-NUCLEOTIDE POLYMORPHISMS | Immunohistochemistry | Dermatitis, Atopic - genetics | Dermatitis, Atopic - epidemiology | Membrane Proteins - genetics | Humans | Cells, Cultured | Gene Expression Regulation | Male | Dermatitis, Atopic - pathology | Gene Expression Profiling | Claudin-1 | Tight Junctions - immunology | Age of Onset | Dermatitis, Atopic - immunology | Polymerase Chain Reaction | Adult | Female | Membrane Proteins - metabolism | Polymorphism, Single Nucleotide | Phosphates | Allergens | Medical colleges | Care and treatment | RNA | Radiation | Fluorescein | Permeability | Sugars | Monosaccharides | Proteins | Studies | Antigens | Psoriasis | Disease | Skin diseases | Dermatitis | Defects
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2014, Volume 71, Issue 2, pp. 327 - 349
Atopic dermatitis is a chronic, pruritic inflammatory dermatosis that affects up to 25% of children and 2% to 3% of adults. This guideline addresses important...
Dermatology | interferon gamma | oral antihistamines | oral steroids | photochemotherapy | cyclosporin A | atopic dermatitis | azathioprine | methotrexate | mycophenolate mofetil | phototherapy | systemic therapy | oral antimicrobials | ULTRAVIOLET-B PHOTOTHERAPY | EXTRACORPOREAL PHOTOCHEMOTHERAPY | UVB PHOTOTHERAPY | RANDOMIZED CONTROLLED-TRIAL | DERMATOLOGY | PSORALEN PHOTOCHEMOTHERAPY | DOUBLE-BLIND | THIOPURINE METHYLTRANSFERASE | STAPHYLOCOCCUS-AUREUS | LONG-TERM TREATMENT | MYCOPHENOLATE-MOFETIL | Medical colleges | Antihistamines | Hospitals | Atopic dermatitis | Practice guidelines (Medicine) | Anti-infective agents | Phototherapy
Dermatology | interferon gamma | oral antihistamines | oral steroids | photochemotherapy | cyclosporin A | atopic dermatitis | azathioprine | methotrexate | mycophenolate mofetil | phototherapy | systemic therapy | oral antimicrobials | ULTRAVIOLET-B PHOTOTHERAPY | EXTRACORPOREAL PHOTOCHEMOTHERAPY | UVB PHOTOTHERAPY | RANDOMIZED CONTROLLED-TRIAL | DERMATOLOGY | PSORALEN PHOTOCHEMOTHERAPY | DOUBLE-BLIND | THIOPURINE METHYLTRANSFERASE | STAPHYLOCOCCUS-AUREUS | LONG-TERM TREATMENT | MYCOPHENOLATE-MOFETIL | Medical colleges | Antihistamines | Hospitals | Atopic dermatitis | Practice guidelines (Medicine) | Anti-infective agents | Phototherapy
Journal Article
Journal of Investigative Dermatology, ISSN 0022-202X, 02/2009, Volume 129, Issue 2, pp. 320 - 322
The eczemas represent a common and diverse group of inflammatory skin diseases whose definitions and pathogenic mechanisms have often been confused and...
HUMAN EPITHELIAL-CELLS | ICHTHYOSIS VULGARIS | FILAGGRIN MUTATIONS | PROLIFERATION | SKIN | EXPRESSION | T-CELLS | IN-SITU | EXPOSURE | THYMIC STROMAL LYMPHOPOIETIN | DERMATOLOGY | Signal Transduction - immunology | Animals | Dermatitis, Atopic - etiology | Eczema - immunology | Humans | Dermatitis, Atopic - immunology | Eczema - etiology | Keratinocytes - immunology
HUMAN EPITHELIAL-CELLS | ICHTHYOSIS VULGARIS | FILAGGRIN MUTATIONS | PROLIFERATION | SKIN | EXPRESSION | T-CELLS | IN-SITU | EXPOSURE | THYMIC STROMAL LYMPHOPOIETIN | DERMATOLOGY | Signal Transduction - immunology | Animals | Dermatitis, Atopic - etiology | Eczema - immunology | Humans | Dermatitis, Atopic - immunology | Eczema - etiology | Keratinocytes - immunology
Journal Article
14.
Full Text
A reassuring rejoinder against malignant influences of topical calcineurin use in children
JAMA Dermatology, ISSN 2168-6068, 06/2015, Volume 151, Issue 6, pp. 587 - 588
Journal Article
Journal of Allergy and Clinical Immunology, The, ISSN 0091-6749, 2014, Volume 133, Issue 2, pp. AB72 - AB72
Journal Article
The Journal of Allergy and Clinical Immunology, ISSN 0091-6749, 10/2018, Volume 142, Issue 4, pp. 1121 - 1130.e7
Nemolizumab, an anti–IL-31 receptor A mAb, improved pruritus, dermatitis, and sleep in adults with moderate-to-severe atopic dermatitis that was inadequately...
pruritus | atopic dermatitis | Monoclonal antibody | IL-31 receptor | nemolizumab | IL-31 | PLACEBO | MANAGEMENT | ECZEMA | GUIDELINES | NATIONAL-HEALTH | RECEPTOR | IMMUNOLOGY | INTERLEUKIN-31 | SKIN BARRIER | CARE | ALLERGY | Viral antibodies | Antibodies | Care and treatment | Pruritus | Atopic dermatitis | Analysis | Edema | FDA approval | Dermatitis | Patients | Asthma | Histamine | Randomization | Sleep | Eczema | Monoclonal antibodies | Population | Skin diseases | Skin | Adults | Safety | Drug dosages
pruritus | atopic dermatitis | Monoclonal antibody | IL-31 receptor | nemolizumab | IL-31 | PLACEBO | MANAGEMENT | ECZEMA | GUIDELINES | NATIONAL-HEALTH | RECEPTOR | IMMUNOLOGY | INTERLEUKIN-31 | SKIN BARRIER | CARE | ALLERGY | Viral antibodies | Antibodies | Care and treatment | Pruritus | Atopic dermatitis | Analysis | Edema | FDA approval | Dermatitis | Patients | Asthma | Histamine | Randomization | Sleep | Eczema | Monoclonal antibodies | Population | Skin diseases | Skin | Adults | Safety | Drug dosages
Journal Article